The registry data suggest improved outcomes without safety concerns, but confirmatory RCTs are needed, a researcher says.

Better devices and changes in implant depth have likely led to fewer LBBBs over time, but the issue needs continued attention ...

The disparate cutoffs may help determine whether a patient should go to the cath lab. Prospective validation comes next.

The target trial emulation study suggests rigid risk thresholds aren’t needed to steer statin use in this group.

Interventional cardiologists say some cases that coders flag and submit to the NCDR aren’t in fact problematic.

Gene-editing therapy, ACS guidelines, and the death of Dimitrios Karmpaliotis were some of TCTMD’s most-read stories this ...

Interventionalists don’t often order a CXR ahead of time, but when it’s already been done, some find the added info useful.

A steady stream of structural trial data, approvals, reimbursement decisions, and real-world rollouts arrived in 2025.

Structural heart news arrived in a steady stream throughout 2025—from pivotal trials to approvals, reimbursement decisions, ...

The year saw the emergence of a new version of an old drug that proved beneficial in patients who have heart failure with ...

The TCTMD journalists look back at the year's memorable moments—and take a few guesses at what's ahead.